Acid citrate dextrose (acd) formula a as a new anticoagulant in the measurement of in vitro platelet aggregation

Pignatelli, Pasquale; Pulcinelli, Fabio M.; Ciatti, Filippo; Pesciotti, Marzia; Sebastiani, Silvia; Ferroni, Patrizia; Gazzaniga, Pier Paolo

doi:10.1002/jcla.1860090211

Cited by 23 publications

(14 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…This finding does not contradict our results from the plasma‐phase platelet count, since the decrease in the plasma‐phase platelet count for the positive control materials could be due to platelet aggregation rather than to surface‐adhered platelets; however, the lack of distinction between surface‐bound platelets on control materials could be due to experimental limitations of the ACP assay for adhered platelet quantification (e.g., inadequate lysing of platelet aggregates). In addition, even though ACD has been commonly used as an anticoagulant for platelet studies for many years and has been shown to be a suitable anticoagulant to characterize platelet aggregation and shear‐induced platelet activation, the calcium‐chelating nature of citrate‐based anticoagulants may suppress platelet adhesion to material surfaces . Evaluation using alternative anticoagulants that can maintain a physiological calcium level will be considered in our future studies.…”

Section: Discussionsupporting

confidence: 93%

Effects of nanotopography on the in vitro hemocompatibility of nanocrystalline diamond coatings

Skoog

Malinauskas

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

Nanocrystalline diamond (NCD) coatings have been investigated for improved wear resistance and enhanced hemocompatibility of cardiovascular devices. The goal of this study was to evaluate the effects of NCD surface nanotopography on in vitro hemocompatibility. NCD coatings with small (NCD-S) and large (NCD-L) grain sizes were deposited using microwave plasma chemical vapor deposition and characterized using scanning electron microscopy, atomic force microscopy, contact angle testing, and Raman spectroscopy. NCD-S coatings exhibited average grain sizes of 50-80 nm (RMS 5.8 nm), while NCD-L coatings exhibited average grain sizes of 200-280 nm (RMS 23.1 nm). In vitro hemocompatibility testing using human blood included protein adsorption, hemolysis, nonactivated partial thromboplastin time, platelet adhesion, and platelet activation. Both NCD coatings demonstrated low protein adsorption, a nonhemolytic response, and minimal activation of the plasma coagulation cascade. Furthermore, the NCD coatings exhibited low thrombogenicity with minimal platelet adhesion and aggregation, and similar morphological changes to surface-bound platelets (i.e., activation) in comparison to the HDPE negative control material. For all assays, there were no significant differences in the blood-material interactions of NCD-S versus NCD-L. The two tested NCD coatings, regardless of nanotopography, had similar hemocompatibility profiles compared to the negative control material (HDPE) and should be further evaluated for use in blood-contacting medical devices. © 2016 Wiley Periodicals, Inc. J Biomed Mater Res Part A: 105A: 253-264, 2017.

show abstract

Section: Discussionsupporting

confidence: 93%

Effects of nanotopography on the in vitro hemocompatibility of nanocrystalline diamond coatings

Skoog

Malinauskas

et al. 2016

J Biomedical Materials Res

View full text Add to dashboard Cite

show abstract

“…The previously reported increase of in vitro platelet responsiveness in ACD vs. Na citrate anticoagulated samples at TO was further confirmed. Moreover, as previously demonstrated, the increased reactivity was more evident for the secondary aggregation, while only slight differences were observed upon stimulation of platelets with threshold concentrations of the various agonists (data not shown) (22). Platelet counts and mean platelet volumes were evaluated on ACD and citrated samples at TO and after 6 and 8 hours of storage.…”

Section: R Es U Ltssupporting

confidence: 65%

“…In a previous report we demonstrated that platelets obtained from ACD Formula A anticoagulated blood showed an over-collagen 1 pg/ml, and AA 0.3 mM; the time required to reach the Mx% with the various agonists, the agonist ECsO forADPand EPI-induced aggregation, and the lag phase for collagenand AA-induced aggregation. all reactivity to the agonists higher than citrated samples ( P < 0.001), suggesting the hypothesis that ACD is a more physiological anticoagulant, which is capable of better maintaining the intraplatelet signal transduction mechanisms during P W preparation, thus improving the overall responsiveness of platelets (22). Therefore the present study was designed to evaluate whether the use ofACD FormulaAmay enhance the survival of platelets during storage, thus allowing the continuance of platelet studies over 3 hours.…”

Section: Introductionmentioning

confidence: 99%

Effects of storage on in vitro platelet responses: Comparison of ACD and Na citrate anticoagulated samples

Pignatelli

Pulcinelli

Ciatti

et al. 1996

J. Clin. Lab. Anal.

View full text Add to dashboard Cite

The present study was designed to evaluate whether the use of acid citrate dextrose (ACD) Formula A may enhance the survival of platelets during storage, thus allowing the continuance of platelet studies over the period of 2–3 hours usually recommended. For this purpose the effects of time on in vitro platelet response to several agonists have been investigated in platelet‐rich plasma (PRP) obtained from blood samples anticoagulated with either Na citrate or ACD Formula A. The analysis of the data obtained in in vitro platelet aggregation studies using various parameters and at different time points demonstrated that storage of PRP obtained from citrated samples caused a marked reduction of platelet responses. This reduction was already evident after 6 hours, and a strong decrease was observed after 8 hours with all the agonists used. On the other hand, storage of ACD anticoagulated blood did not cause any significant decrease of platelet responsiveness up to 6 hours. A reduction of platelet aggregation became evident only after 8 hours, but not to the same extent as the one observed in citrated samples. Therefore, it may be concluded that the use of ACD Formula A as anticoagulant is capable of maintaining a normal platelet responsiveness up to 6–8 hours, thus permitting the investigation of platelet function for periods of time over those commonly recommended. © 1996 Wiley‐Liss, Inc.

show abstract

“…Indeed, ACD-A better maintains the intraplatelet signal transduction mechanisms during PRP preparation, thus improving the overall responsiveness of platelets. 5,6 …”

Section: Methodsmentioning

confidence: 99%

Formulation and Storage of Platelet-Rich Plasma Homemade Product

Bausset¹,

Guy²,

Véran³

et al. 2012

BioResearch Open Access

113

116

View full text Add to dashboard Cite

The platelet-rich plasma (PRP) is an autologous biotherapy based on platelet-healing properties. Here, we developed a simple and reproducible PRP purification protocol based on two successive centrifugations. We evaluated different centrifugation speeds and time-storage durations on the platelet quantity and quality. Sterility and stability of our PRP homemade product were also performed. We prepared PRP from 54 healthy volunteers. We tested activation state, reactivity, and stability of platelets by flow cytometry using basal and adenosine diphosphate (ADP)-induced P-selectin expression markers; growth factor release after platelet activation by an enzyme-linked immunosorbent assay (ELISA); platelet aggregation capacity by aggregrometry assays; clot formation and retraction by thromboelastography; and platelet morphology by ultrastructural analysis. About 130 and 250 g successive speed centrifugations further concentrated platelets while preserving their bioactivity during 6 h (after that, platelet functions were significantly altered). In these conditions, we obtained a highly concentrated pure PRP product (with a low leukocyte count) suitable to study platelet properties. To avoid the loss of efficacy, we recommend injecting PRP under 3 h after preparation.

show abstract

Acid citrate dextrose (acd) formula a as a new anticoagulant in the measurement of in vitro platelet aggregation

Cited by 23 publications

References 11 publications

Effects of nanotopography on the in vitro hemocompatibility of nanocrystalline diamond coatings

Effects of nanotopography on the in vitro hemocompatibility of nanocrystalline diamond coatings

Effects of storage on in vitro platelet responses: Comparison of ACD and Na citrate anticoagulated samples

Formulation and Storage of Platelet-Rich Plasma Homemade Product

Contact Info

Product

Resources

About